Tavapadon – Medxy AI

Tavapadon in Early Parkinson’s Disease: Promising Phase 3 Trial Highlights Safety and Motor Symptom Benefits

By MedXY 08/09/2026

The phase 3 TEMPO-2 trial demonstrates that flexible-dose tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improves motor symptoms in early Parkinson's disease with a manageable safety profile, warranting further long-term study.

Neurology news

Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial

By MedXY 05/20/2026

In a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.

Clinical Updates Neurology news

Selective D1/D5 Receptor Agonism in Parkinson Disease: Insights from the TEMPO-3 Phase 3 Trial of Tavapadon

By MedXY 03/27/2026

The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a novel selective D1/D5 agonist, significantly improves daily 'good-on-time' and reduces 'off-time' in Parkinson’s disease patients with motor fluctuations, presenting a potential shift in adjunctive therapy.

Neurology news

Selective D1/D5 Agonism: TEMPO-3 Trial Positions Tavapadon as a Significant Advancement for Parkinson’s Motor Fluctuations

By MedXY 03/22/2026

The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a selective D1/D5 agonist, significantly increases 'good-on-time' and reduces 'off-time' in Parkinson’s patients with motor fluctuations, offering a favorable safety profile compared to traditional D2/D3 agonists.